ReviewCell biochemistry and biophysics2024
Cardiometabolic Disorder and Erectile Dysfunction.
Review in Cell biochemistry and biophysics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Bakh formula ameliorates high-fat diet-induced erectile dysfunction in rats via coordinated restoration of metabolic and tissue homeostasis.Sexual medicine · 2026Article
- Intervening at the microbial crossroads: targeting inflammation across the oral-gut-reproductive microbiome crosstalk in atherosclerosis.Antonie van Leeuwenhoek · 2026Review
- Quercetin alleviates radiation-induced erectile dysfunction by modulating oxidative stress and apoptosis through the Nrf2/HO-1 pathway.European journal of medical research · 2026Article
- Genetic biomarkers associated with risk and therapeutic response in erectile dysfunction: a systematic review.Frontiers in pharmacology · 2026Review
- L-arginine attenuates cisplatin-induced sexual dysfunction in male Wistar rats by modulating circulating testosterone and NO/cGMP signaling.JBRA assisted reproduction · 2026Article
- Vascular aging-driven erectile dysfunction: pathophysiological mechanisms and emerging therapies-a narrative review.Translational andrology and urology · 2025Review
- The aging male: impact of aging on male reproduction.Biogerontology · 2025Review
- Micronized purified flavonoid fraction (daflon) improves sexual function by modulating NF-kB /NO/cGMP and steroidogenic signaling in cisplatin-treated male Wistar rats.Biochemistry and biophysics reports · 2025Article
- Review
- Article
- Unraveling the complexity of the impact of physical exercise on male reproductive functions: a review of both sides of a coin.Frontiers in physiology · 2024Review
- A comprehensive analysis of erectile dysfunction prevalence and the impact of prostate conditions on ED among US adults: evidence from NHANES 2001-2004.Frontiers in endocrinology · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erectile dysfunction (ED), which is defined as the inability to attain and maintain a satisfactory penile erection to sufficiently permit sexual intercourse, is a consequence and also a cause of cardiometabolic disorders like diabetes mellitus, systemic hypertension, central obesity, and dyslipidemia. Although there are mounting and convincing pieces of evidence in the literature linking ED and cardiometabolic disorders, impairment of nitric oxide-dependent vasodilatation seems to be the primary signaling pathway. Studies have also implicated the suppression of circulating testosterone, increased endothelin-1, and hyperactivation of Ang II/ATIr in the pathogenesis of ED and cardiometabolic disorders. This study provides comprehensive details of the association between cardiometabolic disorders and ED and highlights the mechanisms involved. This would open areas to be explored as therapeutic targets in the management of ED and cardiometabolic disorders. It also provides sufficient evidence establishing the need for the management of cardiometabolic disorders as an adjunct therapy in the management of ED.
Indexed as
Identifiers
38907942What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.